Objective To investigate the progress of nationwide echinococcosis control program in China in 2024, and to summarize the experiences and challenges, so as to provide insights into optimization of echinococcosis control strategies and measures. Methdos Data pertaining to national echinococcosis control programs in endemic areas of China in 2024 were collected from the Information Management System for Parasitic Disease Control operated by Chinese Center for Disease Control and Prevention to create a database. A descriptive analysis was performed to understand human echinococcosis tests and treatments, prevalence of infections in infectious sources, and prevalence of echinococcosis in intermediate hosts, and compare them with the data from 2020 to 2023. Intergroup comparisons were performed using Pearson’s chi-square test and Cochran-Armitage trend test. Results A total of 23 622 prevalent echinococcosis cases were found in 370 endemic counties across China by the end of 2024, with a prevalence rate of 53.73/10⁵ (23 622/43 963 728), appearing a 15.40% decrease relative to 2020 (63.51/10⁵). A total of 2 159 incident echinococcosis cases were reported in China in 2024, showing a 13.63% increase relative to 2020 (1 900 cases), and 10.79% (233/2 159) of cases were detected among individuals at ages of under 12 years. Abdominal ultrasound scans were performed for human echinococcosis screening in China at 5.640 4 million person-times in 2024, and suspected cases positive for ultrasound scans were subjected to serological tests at 12 479 person-times. A total of 16 717 individuals received chemotherapy against echinococcosis and 2 061 individuals received surgical treatments for echinococcosis in 2024, including 69.29% of cystic echinococcosis patients (1 428/2 061) and 24.55% of alveolar echinococcosis patients (506/2 061). The 2024 follow-up outcomes revealed that there were 2 499 cases with cure, 18 294 cases with responses to treatments, 4 511 cases with failure in treatments, 371 deaths (the causes of the deaths were not echinococcosis), 483 cases excluded from the study, 231 cases lost to follow-up, 169 cases with incompletion of the follow-up, and 88 cases migrating to other places. In 2024, there were 2 073 297 dogs in echinococcosis-endemic townships in China, including 1 960 195 dogs registered for management. Deworming was conducted in dogs in 35 146 villages, including domestic dog deworming at 20 989 364 times, and wild canines deworming with 347 167 doses. The prevalence of positive Echinococcus coproantigen results was 0.51% (2 109/411 144) in domestic dogs, appearing a tendency towards a rise since 2021 (Z = 3.66, P < 0.05), and was 3.33% (2 437/73 088) in wild canines, showing a tendency towards a rise since 2021 (Z = 31.37, P < 0.05). In 2024, the prevalence of echinococcosis was 0.92% (1 273/138 373) in livestock, appearing a tendency towards a rise since 2021 (Z = 10.20, P < 0.05), and was 0.57% (282/49 780) in field rodents, appearing a tendency towards a decline since 2021 (Z = -11.31, P < 0.05). Conclusion The prevalence of echinococcosis had been basically controlled in China in 2024; however, the rebound of incident cases and an increase in the prevalence of echinococcosis in infectious sources indicate a risk of resurgence. Future echinococcosis control efforts should continue to strengthen integrated control and cross-sectoral collaboration, and focus on precise management of infectious sources in the context of the One Health concept, improved grassroots capacity, and increased investment in scientific research to overcome key technical bottlenecks, so as to improve echinococcosis control capabilities in China.